Related Experiment Video

Updated: May 15, 2026

Coronary Artery Ligation and Intramyocardial Injection in a Murine Model of Infarction
07:41

Coronary Artery Ligation and Intramyocardial Injection in a Murine Model of Infarction

Published on: June 7, 2011

Regenerative strategies for preserving and restoring cardiac function

Amanda Finan1, Feng Dong, Marc Steven Penn

  • 1Department of Molecular Biology, Case Western Reserve University, Cleveland, OH 44106, USA.

Frontiers in Bioscience (Elite Edition)
|January 2, 2013
PubMed

Insights

Cardiovascular regenerative medicine advances stem cell therapy for heart repair. Future treatments may combine programmed stem cells with biopharmaceuticals to enhance natural healing mechanisms.

Area of Science:

  • Cardiovascular regenerative medicine
  • Cardiac repair and regeneration

Background:

  • Traditional cardiovascular disease treatments lack regenerative capabilities.
  • Stem cell therapy offers a promising approach to repair damaged heart tissue and prevent cardiac dysfunction.

Purpose of the Study:

  • To review the clinical applications of exogenous stem cell populations in cardiac repair.
  • To discuss the molecular pathways involved in endogenous stem cell response to cardiac injury.
  • To explore future therapeutic strategies involving stem cells and biopharmaceuticals.

Main Methods:

  • Review of current literature on stem cell therapy for myocardial injury.
  • Analysis of molecular pathways orchestrating endogenous stem cell responses.
  • Formulation of a combined therapeutic strategy.

Main Results:

  • Exogenous stem cell populations show potential for cardiac repair.
  • Understanding of molecular pathways for endogenous stem cell activation is growing.
  • A combination approach is proposed for future cardiac regeneration.

Conclusions:

  • Stem cell therapy is a viable option for treating cardiac dysfunction.
  • Manipulating endogenous pathways offers a future therapeutic avenue.
  • Combining programmed stem cells with biopharmaceuticals may optimize cardiac regeneration.

More Related Videos

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes09:16

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes

Published on: June 3, 2018

Neonatal Cardiac Scaffolds: Novel Matrices for Regenerative Studies08:16

Neonatal Cardiac Scaffolds: Novel Matrices for Regenerative Studies

Published on: November 5, 2016

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...